Signati™ Medical Announces Dr. LeRoy Jones Has Been Appointed as a Professor of Urology at the University of Texas San AntonioProvidence, RI, March 12, 2026 (GLOBE NEWSWIRE) -- Dr. Jones is widely regarded as one of the most accomplished prosthetic surgeons in the nation, with over 30 years of clinical experience.
Signati™ Medical Successfully Completes IDE Trial for Separo™ Vessel Sealing System and Initiates FDA Market Clearance ProcessProvidence, RI, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Signati™ Medical is proud to announce the successful completion of its Investigational Device Exemption (IDE) trial evaluating the Separo™ Vessel Sealing System for vasectomy procedures. All eight patients enrolled in the study met the primary endpoint, marking a significant milestone in the development of this groundbreaking technology.
Signati Medical Announces Completion of Enrollment in First-in-Human Clinical Trial for Groundbreaking Sealed Vasectomy ProcedureProvidence, RI, July 18, 2024 (GLOBE NEWSWIRE) -- Signati Medical™, a medical device company dedicated to advancing men’s health, today announced the successful completion of enrollment in its Investigational Device Exemption (IDE) trial evaluating the safety and efficacy of its proprietary Signati Separo™ Vessel Sealing System for vasectomy procedures.
Signati™ Medical Enrolls First Patient in Groundbreaking Sealed Vasectomy Procedure TrialProvidence, RI, July 18, 2024 (GLOBE NEWSWIRE) -- Signati Medical™, a medical device company dedicated to advancing men’s health, today announced the successful completion of enrollment in its Investigational Device Exemption (IDE) trial evaluating the safety and efficacy of its proprietary Signati Separo™ Vessel Sealing System for vasectomy procedures.
Signati™ Medical Enrolls First Patient in Groundbreaking Sealed Vasectomy Procedure TrialProvidence, RI, April 09, 2024 (GLOBE NEWSWIRE) -- Signati™ Medical, a medical device company dedicated to advancing men’s health, today announced the successful enrollment of the first patient in its Investigational Device Exemption (IDE) trial for the Signati Separo™, a revolutionary new device designed to streamline the vasectomy procedure.
Signati™ Medical, Inc. Announces Board Member Dr. Jones Joins Urology AustinProvidence, RI, Feb. 12, 2024 (GLOBE NEWSWIRE) -- LeRoy Jones, MD, Board-Certified Urologist and Signati™ Medical, Inc. Board Member, starts a new chapter in his career at Urology Austin. Dr. Jones has been on the leading edge of men’s sexual health and prosthetic surgery for decades. As an industry leader in prosthetic surgery, Dr. Jones has performed more than 3,500 penile implants and artificial urinary sphincter procedures. He is among the most experienced prosthetic surgeons in the world. He specializes in erectile dysfunction, erectile growth enhancement, Peyronies Disease, low testosterone, premature ejaculation, urinary incontinence, and male infertility — vasectomies, reversals, and microsurgery.
Signati™ Medical, Inc. Receives FDA Approval for IDE StudyProvidence, RI, Dec. 20, 2023 (GLOBE NEWSWIRE) -- The FDA has officially approved Signati™ Medical’s Investigational Device Exemption (IDE) study! This comes on the company’s 5 year anniversary. "Our investments in research and development along with technological advancements have enabled Signati to develop the first minimally invasive vasectomy product in a market that is on tract to achieve remarkable growth," says William Prentice, Signati Medical CEO. Louisiana State University Medical Center has agreed to conduct the study which should start in January 2024.
Signati Medical™ Receives Additional Patent Protection for its Innovative Bipolar HandpieceProvidence, RI, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Signati Medical™ is pleased to announce the issue of US patent 11,723,680 covering critical features of the bipolar handpiece used in Signati’s Sealed Vasectomy Procedure (SVP)™.
Signati™ Medical Files IDE Study with FDAProvidence, RI, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Signati™ Medical has officially filed their IDE study with the FDA. An Investigational Device Exemption (IDE) allows the investigational device to be used in a clinical study in order to collect safety and effectiveness data. All clinical evaluations of investigational devices must have an approved IDE before the study begins. An approved IDE permits a device to be shipped lawfully for the purpose of conducting investigations of the device without complying with other requirements of the Food, Drug, and Cosmetic Act (FD&C Act) that would apply to devices in commercial distribution.
Signati™️ Medical, Inc. Announces Dr. LeRoy Jones Has Been Appointed to Its Board of DirectorsProvidence, RI, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Signati™️ Medical, Inc. announced today that Dr. LeRoy Jones has been appointed to its Board of Directors. Dr. Jones is considered an authority in the field of sexual medicine, having performed over 3000 prosthetic surgeries. He has numerous publications in the field of sexual medicine. Dr. Jones is internationally recognized and has taught surgery in over 26 countries throughout the world. He is the past president of The Society of Urologic Prosthetic Surgeons and is an active member of the Sexual Medicine Society of North America. Dr. Jones is currently in private practice with Urology San Antonio in San Antonio, Texas.
Signati™ Medical, Inc. Completes Acquisition of SuperiorVAS Intellectual Property and TechnologyProvidence, RI, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Signati™ Medical, Inc. today announced that it has completed the acquisition of all of the intellectual property and technology of SuperiorVAS, LLC, a privately held company in Raleigh, NC. The IP covers methods to create a vasectomy through ablation of the vas deferens—an advancement in a critical technology. Terms of the agreement were not disclosed.
